TITLE

Oral fingolimod was more effective than intramuscular interferon for relapsing-remitting multiple sclerosis

AUTHOR(S)
Hughes, James
PUB. DATE
May 2010
SOURCE
ACP Journal Club;5/18/2010, Vol. 152 Issue 5, p5
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a study that discusses the effective use of oral fingolimod and intramuscular interferon β in patients with relapsing-remitting multiple sclerosis (MS). Reportedly, doses of oral fingolimod and interferon β were given to thousands of patients during the clinical trail of MS. However, it concludes that doses of oral fingolimod are stated to be more effective than interferon β but its higher dose could release serious adverse events.
ACCESSION #
51696573

 

Related Articles

  • Emerging Therapies in Relapsing-Remitting Multiple Sclerosis. Marriott, James J.; O'Connor, Paul W. // Reviews on Recent Clinical Trials;Sep2010, Vol. 5 Issue 3, p179 

    Disease modifying therapy (DMT) first became available for relapsing-remitting multiple sclerosis (RRMS) fifteen years ago with the development of the moderately effective injectable agents interferon (IFN)-? and glatiramer acetate (GA). The subsequent licensure of mitoxantrone (MX) and...

  • Early treatment for MS beneficial. Drennan, Vari // Primary Health Care;Oct2007, Vol. 17 Issue 8, p6 

    The article reports on the study to determine whether early treatment of interferon beta prevents the growth of confirmed disability in multiple sclerosis (CDMS). This is measured through expanded disability status scale. Clinical trials for patients receiving the drug are explored. These show...

  • Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsing -- remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Lanzillo, Roberta; Orefice, Giuseppe; Quarantelli, Mario; Rinaldi, Carlo; Prinster, Anna; Ventrella, Gianluca; Spitaleri, Daniele; Lus, Giacomo; Vacca, Giovanni; Carotenuto, Barbara; Salvatore, Elena; Brunetti, Arturo; Tedeschi, Gioacchino; Morra, Vincenzo Brescia // Multiple Sclerosis (13524585);Apr2010, Vol. 16 Issue 4, p450 

    A large body of evidence suggests that, besides their cholesterol-lowering effect, statins exert anti-inflammatory action. Consequently, statins may have therapeutic potential in immune-mediated disorders such as multiple sclerosis. Our objectives were to determine safety, tolerability and...

  • Copaxone slows disability progression and prevents relapses in MS patients.  // PharmaWatch: CNS;November 2004, Vol. 3 Issue 11, p5 

    Discusses the ability of Copaxone therapy to slow disability progression and prevent relapses in relapsing-remitting multiple sclerosis patients in reference to study data presented before a European committee. Effectiveness in comparison to interferon therapies; Results of clinical trials for...

  • Rebif trial disappointing for secondary-progressive MS.  // Inside MS;Fall99, Vol. 17 Issue 4, p27 

    Reports that the results of a placebo-controlled clinical trial of the drug Rebif for secondary-progressive multiple sclerosis (MS) were disappointing. Positive observations from the study; United States Food and Drug Administration's denial of approval for the marketing of Rebif in the...

  • EMA Seeks Industry Comments On IFN-Beta Draft Guideline. Moran, Nuala // BioWorld International;1/25/2012, Vol. 17 Issue 4, p1 

    The article focuses on the draft guideline on a proposed route for approving interferon beta (IFN-beta) for the treatment of multiple sclerosis (MS) published by the European Medicines Agency (EMA). The agency is seeking industry comments on the guideline aimed at establishing regulatory...

  • Spotlight on Subcutaneous Recombinant Interferon-β-1a (Rebif®) in Relapsing-Remitting Multiple Sclerosis. Murdoch, David; Lyseng-Williamson, Katherine A. // BioDrugs;2005, Vol. 19 Issue 5, p323 

    Subcutaneous recombinant interferon-β-1a (Rebif®) 22 or 44µg three times weekly is a valuable option in the first-line treatment in patients with relapsing-remitting multiple sclerosis. It has shown benefits on outcome measures related to relapses, progression of disability, and...

  • Efficacy and Safety of Prolonged Immunomodulatory Treatment with Interferon Beta. Demina, T. L.; Khachanova, N. V.; Davydovskaya, M. V.; Popova, N. F.; Gusev, E. I. // Neuroscience & Behavioral Physiology;Jun2009, Vol. 39 Issue 5, p497 

    The article presents several studies which demonstrate the efficacy of long-term immunomodulatory therapy with interferon beta for multiple sclerosis (MS). It notes that the European Study of Secondary Progressive MS does not only reveals the long-tem effects of interferon therapy but also...

  • ESCLEROSIS MÚLTIPLE: Por fin, primeros ensayos clínicos controlados, Fase III, con terapias orales para la esclerosis múltiple.  // Revista Mexicana de Neurociencia;mar/abr2010, Vol. 11 Issue 2, p172 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics